Kintegral Advisory LLC Has $10.08 Million Stake in AbbVie Inc. (NYSE:ABBV)

Kintegral Advisory LLC trimmed its holdings in AbbVie Inc. (NYSE:ABBV - Free Report) by 4.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 56,740 shares of the company's stock after selling 2,643 shares during the period. AbbVie comprises about 1.0% of Kintegral Advisory LLC's investment portfolio, making the stock its 20th largest holding. Kintegral Advisory LLC's holdings in AbbVie were worth $10,083,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Redmond Asset Management LLC acquired a new position in shares of AbbVie during the fourth quarter worth about $1,623,000. Oxbow Advisors LLC boosted its position in shares of AbbVie by 1.3% during the fourth quarter. Oxbow Advisors LLC now owns 7,120 shares of the company's stock worth $1,265,000 after buying an additional 88 shares during the period. Element Wealth LLC raised its holdings in AbbVie by 1.4% during the fourth quarter. Element Wealth LLC now owns 5,405 shares of the company's stock worth $960,000 after acquiring an additional 77 shares in the last quarter. Prentice Wealth Management LLC raised its holdings in AbbVie by 3.1% during the fourth quarter. Prentice Wealth Management LLC now owns 6,267 shares of the company's stock worth $1,114,000 after acquiring an additional 190 shares in the last quarter. Finally, Bell Bank raised its holdings in AbbVie by 9.5% during the fourth quarter. Bell Bank now owns 73,150 shares of the company's stock worth $12,999,000 after acquiring an additional 6,333 shares in the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. BMO Capital Markets upped their target price on AbbVie from $208.00 to $215.00 and gave the stock an "outperform" rating in a report on Monday, February 3rd. Piper Sandler Companies reiterated an "overweight" rating and set a $220.00 target price on shares of AbbVie in a report on Tuesday, December 17th. Leerink Partners upgraded AbbVie from a "market perform" rating to an "outperform" rating and set a $206.00 target price on the stock in a report on Friday, November 22nd. Morgan Stanley upped their target price on AbbVie from $224.00 to $239.00 and gave the stock an "overweight" rating in a report on Monday, February 3rd. Finally, UBS Group upped their target price on AbbVie from $181.00 to $190.00 and gave the stock a "neutral" rating in a report on Monday, February 3rd. Five analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, AbbVie has an average rating of "Moderate Buy" and a consensus target price of $208.35.

Insider Activity

In related news, SVP Kevin K. Buckbee sold 1,800 shares of the stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $172.24, for a total transaction of $310,032.00. Following the sale, the senior vice president now owns 6,983 shares of the company's stock, valued at $1,202,751.92. This represents a 20.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.25% of the stock is owned by company insiders.

AbbVie Price Performance

AbbVie stock opened at $202.03 on Friday. AbbVie Inc. has a 12 month low of $153.58 and a 12 month high of $207.32. The stock's 50 day moving average is $180.68 and its 200-day moving average is $186.29. The company has a current ratio of 0.66, a quick ratio of 0.54 and a debt-to-equity ratio of 17.94. The company has a market capitalization of $356.64 billion, a price-to-earnings ratio of 84.18, a PEG ratio of 1.58 and a beta of 0.58.

AbbVie (NYSE:ABBV - Get Free Report) last posted its earnings results on Friday, January 31st. The company reported $2.16 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.82). AbbVie had a net margin of 7.59% and a return on equity of 296.28%. During the same period last year, the company posted $2.79 earnings per share. Equities research analysts expect that AbbVie Inc. will post 12.32 EPS for the current year.

AbbVie Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, May 15th. Stockholders of record on Tuesday, April 15th will be given a $1.64 dividend. This represents a $6.56 annualized dividend and a dividend yield of 3.25%. The ex-dividend date of this dividend is Tuesday, April 15th. AbbVie's payout ratio is 273.33%.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.